Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

8MM Respiratory Syncytial Virus Prophylaxis Drug Forecast Report 2025: A $7.2 Billion Market by 2030, Prophylactic Options to Continue to Diversify Due to Strength of Late-stage Pipeline

globenewswire.com
AZN AstraZeneca is mentioned as a current and future player in the RSV prophylaxis market with its products Synagis and Beyfortus. The company's involvement contributes to the market's growth and diversification. ABBV SNY Sanofi is a key player in the RSV prophylaxis market, with its product Beyfortus and pipeline candidates SP-0256, SP-0274, and SP-0125. This indicates ongoing development and market presence. MRK Merck & Co. is mentioned for its RSV prophylaxis drug Enflonsia, contributing to the diversification of treatment options in the growing RSV market. GSK GSK is a significant player in the RSV prophylaxis market with its vaccine Arexvy and pipeline candidate GSK-3888550A, indicating active development and market participation. PFE Pfizer is mentioned for its RSV vaccine Abrysvo, contributing to the growing and diversifying RSV prophylaxis market. MRNA Moderna is mentioned for its RSV vaccine mRESVIA, indicating its participation in the expanding RSV prophylaxis market.

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Respiratory Syncytial Virus Prophylaxis: Eight-Market Drug Forecast and Market Analysis - Update" report has been added to ResearchAndMarkets.com's offering.

The report provides an in-depth assessment of the RSV prophylaxis market including disease overview, epidemiology, disease management, current treatment options, unmet needs and opportunities, R&D strategies, pipeline assessment, current and future players, and market outlook.

Across the 8MM, The analyst expects the RSV prophylaxis market to grow at a compound annual growth rate (CAGR) of 28.6% over the 2020-30 forecast period, reaching $7.2 billion by 2030. In 2020, the RSV prophylaxis market was valued at $582M, with all sales attributable to AstraZeneca/AbbVie's Synagis (palivizumab), a monoclonal antibody (mAb) indicated for use in high-risk infants.

The RSV prophylaxis market has undergone significant growth and diversification in the following years owing to the launch of two more mAbs, AstraZeneca/Sanofi's Beyfortus (nirsevimab) and Merck &Co's Enflonsia (clesrovimab), as well as the first RSV vaccines, GSK's Arexvy, Pfizer's Abrysvo, and Moderna's mRESVIA. Five vaccines in late-stage development will also drive market growth. These are GSK's GSK-3888550A, AdVaccine's BARS-13, and Sanofi's SP-0256, SP-0274, and SP-0125.

Key Highlights

Scope

Companies Featured

Key Topics Covered:

1 Respiratory Syncytial Virus Prophylaxis: Executive Summary - Updated July 2025, based on events up to July 2025

1.1 Summary of changes

1.2 RSV prophylaxis market to reach $7.2 billion by 2030

1.3 Unmet needs remain despite influx of novel products

1.4 Prophylactic options to continue to diversify due to strength of late-stage pipeline

1.5 What do physicians think?

2 Introduction - Updated July 2025, based on events up to July 2025

2.1 Catalyst

2.2 Related reports

2.3 Upcoming reports

3 Disease Overview - Updated Nov 2024, based on events up to Nov 2024

3.1 Etiology and pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

4 Epidemiology - Updated Aug 2021, based on events up to Aug 2021

4.1 Disease background

4.1.1 Risk factors and comorbidities

4.2 Global and historical trends

4.3 Forecast methodology

4.3.1 Sources

4.3.2 Forecast assumptions and methods

4.4 Epidemiological forecast for RSV prophylactic population (2020-30)

4.4.1 Number of preterm births by gestational age

4.4.2 Preterm infants with CLD

4.4.3 Number of live births with hemodynamically significant heart disease and congenital lung disease

4.4.4 Diagnosed prevalent cases of DMD

4.4.5 Diagnosed prevalent cases of SMA

4.4.6 Number of third-trimester pregnant women

4.4.7 Number of adults living in nursing homes/long-term care institutions

4.5 Discussion

4.5.1 Epidemiological forecast insight

4.5.2 Limitations of the analysis

4.5.3 Strengths of the analysis

5 Disease Management - Updated July 2025, based on events up to July 2025

5.1 Diagnosis

5.2 Prophylaxis

5.3 Treatment

5.4 KOL insights on disease management

6 Current Treatment Options - Updated July 2025, based on events up to July 2025

6.1 Overview

7 Unmet Needs and Opportunity Assessment - Updated July 2025, based on events up to July 2025

7.1 Overview

7.2 Increased diagnostic testing

7.3 Increased research and awareness of long-term sequelae

7.4 Combination vaccines

7.5 Prophylaxis for immunocompromised patients

8 R&D Strategies - Updated July 2025, based on events up to July 2025

8.1 Overview

8.1.1 Leveraging novel vaccine technologies and strategies

8.1.2 Development of prophylactic antibodies with improved dosing and efficacy

8.2 Clinical trial design

8.2.1 Clinical trial design for RSV prophylactics for maternal immunization

8.2.2 Clinical trial design for RSV prophylactics for pediatric immunization

8.2.3 Clinical trial design for RSV prophylactics for adult immunization

9 Pipeline Assessment - Updated July 2025, based on events up to July 2025

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis - Updated July 2025, based on events up to July 2025

10.1 Overview

10.2 Competitive assessment

10.2.1 Pipeline maternal vaccine products

10.2.2 Pipeline vaccine products for adults

11 Current and Future Players - Updated July 2025, based on events up to July 2025

11.1 Overview

11.2 Deal-making trends

12 Market Outlook - Updated July 2025, based on events up to July 2025

12.1 Global markets

12.1.1 Forecast

12.1.2 Drivers and barriers

12.2 US

12.2.1 Forecast

12.2.2 Key events

12.2.3 Drivers and barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key events

12.3.3 Drivers and barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key events

12.4.3 Drivers and barriers

12.5 Australia

12.5.1 Forecast

12.5.2 Key events

12.5.3 Drivers and barriers

13 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/gimrsj

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.